Vertex Pharmaceuticals (VRTX) Accumulated Depreciation & Amortization (2009 - 2025)

Vertex Pharmaceuticals' Accumulated Depreciation & Amortization history runs 17 years deep, the most recent figure standing at $1.2 billion for Q4 2025.

• In Q4 2025, Accumulated Depreciation & Amortization rose 13.08% year-over-year to $1.2 billion; the TTM figure through Dec 2025 stood at $1.2 billion (up 13.08% YoY), while the FY2025 annual figure was $1.2 billion, up 13.08% from the prior year.
• Accumulated Depreciation & Amortization was $1.2 billion for Q4 2025 at Vertex Pharmaceuticals, up from $1.1 billion in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $1.2 billion in Q4 2025 to a low of $896.0 million in Q4 2021.
• Historically, Accumulated Depreciation & Amortization has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2024.
• The sharpest annual moves came in 2023 and 2024: Accumulated Depreciation & Amortization grew 15.73% in 2023, then fell 10.44% in 2024.
• A 5-year view of Accumulated Depreciation & Amortization shows it stood at $896.0 million in 2021, then climbed by 14.65% to $1.0 billion in 2022, then advanced by 15.73% to $1.2 billion in 2023, then dropped by 10.44% to $1.1 billion in 2024, then advanced by 13.08% to $1.2 billion in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $1.2 billion (Q4 2025), $1.1 billion (Q4 2024), and $1.2 billion (Q4 2023), per Business Quant data.